Related Experiment Video
Updated: Jun 9, 2025
07:53
Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer
Published on: October 13, 2023
1.4K
Enhancing Intrapleural Hyperthermic Chemotherapy for Lung Cancer: Insights from 3D and PDX Models
Jung Young Shin1, Mi Ran Lee1, Kyung Ah Choi2
1Laboratory of Medical Oncology, Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Cancers
|October 26, 2024
Summary
Intrapleural hyperthermic chemotherapy (IPHC) enhances cisplatin
Area of Science:
- Oncology
- Cancer Biology
- Drug Development
Background:
- Malignant pleural effusion (MPE) signifies advanced lung cancer with poor prognosis.
- Intrapleural hyperthermic chemotherapy (IPHC) shows promise for MPE but requires mechanistic understanding.
- Hyperthermia may overcome drug resistance in lung cancer.
Purpose of the Study:
- To investigate the impact of hyperthermia on cisplatin cytotoxicity in lung cancer.
- To evaluate the efficacy of IPHC in preclinical lung cancer models.
Main Methods:
- Lung cancer cell lines and patient-derived cells were treated with cisplatin at varying temperatures (37°C, 43°C, 45°C) and durations.
- Antiproliferative effects were assessed using LDH and CCK-8 assays.
- IPHC efficacy was validated in a patient-derived xenograft (PDX) model, analyzing tumor growth and protein expression.
Main Results:
- Hyperthermia significantly boosted cisplatin's antitumor effects at 43°C and 45°C.
- IPHC demonstrated increased tumor inhibition, necrosis, and delayed regrowth in the PDX model.
- Hyperthermia reduced EGFR expression and increased apoptosis markers (cleaved PARP, caspase-3).
Conclusions:
- IPHC combined with cisplatin shows enhanced efficacy against lung cancer, including drug-resistant types.
- This approach holds potential for treating advanced lung cancer with MPE or pleural metastasis.
- IPHC may improve patient outcomes in advanced lung cancer settings.
